Business
Cara Therapeutics Announces Oral KORSUVA™ (difelikefalin) Data Selected for Late-Breaking Presentation at 2022 American Academy of Dermatology Annual Meeting
Oral presentation will include biomarker data from KARE Phase 2 clinical trial of Oral KORSUVA™ (difelikefalin) for the treatment of moderate-to-severe
About this update from Tvardi Therapeutics, Inc.
[{"type":"text","content":"Oral presentation will include biomarker data from KARE Phase 2 clinical trial of Oral KORSUVA™ (difelikefalin) for the treatment of moderate-to-severe pruritus in atopic dermatitis patients Oral KORSUVA (difelikefalin) Phase 3 pruritus programs in non-dialysis dependent advanced chronic kidney disease and atopic dermatitis, respectively, to be discussed during Company’s virtual R&D event on March 11, 2022, at 1 p.m. ET STAMFORD, Conn., March 08, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced biomarker data from the KARE Phase 2 clinical trial evaluating Oral KORSUVA™ (difelikefalin) for the treatment of moderate-to-severe pruritus in atopic dermatitis patients will be presented in a late-breaking oral presentation at the 2022 American Academy of Dermatology (AAD) Annual Meeting, to be held March 25-29, 2022, in Boston, MA. Details for the late-breaking oral presentation are as follows: Title: Oral Difelikefalin Improves Itch and Inflammatory Biomarkers in Atopic Dermatitis Subjects With Moderate-to-Severe PruritusSession: S026 – Late-Breaking Research: Clinical Trials Date and Time: Saturday, March 26, 2022, 9:40 a.m. ETLocation: Room 210APresenter: Paola Facheris, MD, Icahn School of Medicine at Mount Sinai, New York, NY; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy Virtual R&D Event As previously announced, Cara Therapeutics will be hosting a virtual R&D event at 1:00 p.m. ET on March 11, 2022, which will focus on the initiation of Oral KORSUVA (difelikefalin) Phase 3 programs for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis, respectively. An interactive Q&A session will follow the presentation. Presenters will include: Christopher Posner, President & Chief Executive Officer and Director of Cara TherapeuticsJoana Goncalves, MD, Chief Medical Officer of Cara TherapeuticsBrian Kim, MD, MTR, Icahn School of Medicine at Mount Sinai, NYJonathan Silverberg, MD, PhD, MPH, George Washington University School of Medicine and Health Sciences A live audio webcast of the presentation and accompanying slides will be accessible under “Events & Presentations” ...